1	Wide mismatches in the sequences of primers and probes for Monkeypox
2	virus diagnostic assays
3	
4	Fuqing Wu ¹ *, Jeremiah Oghuan ¹ , Anna Gitter ¹ , Kristina D. Mena ¹ , Eric L. Brown ¹
5	
6	
7	1: The University of Texas Health Science Center at Houston, School of Public Health
8	Houston, Texas, USA 77030
9	
10	* Correspondence to FW at fuqing.wu@uth.tmc.edu.
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

24 Abstract

25 Rapid and accurate diagnosis of infections is fundamental to containment of disease. Several 26 monkeypox virus (MPV) real-time diagnostic assays have been recommended by the CDC; 27 however, the specificity of the primers and probes in these assays for the ongoing MPV outbreak 28 has not been investigated. We analyzed the primer and probe sequences present in the CDC 29 recommended monkeypox virus (MPV) generic real-time PCR assay by aligning those 30 sequences against 1,730 MPV complete genomes reported in 2022 worldwide. Sequence 31 mismatches were found in 99.08% and 97.46% of genomes for the MPV generic forward and 32 reverse primers, respectively. Mismatch-corrected primers were synthetized and compared to the 33 generic assay for MPV detection. Results showed that the two primer-template mismatches 34 resulted in a ~11-fold underestimation of initial template DNA in the reaction and 4-fold increase 35 in the 95% LOD. We further evaluated the specificity of seven other real-time PCR assays used 36 for MPV and orthopoxvirus (OPV) detection and identified two assays with the highest matching 37 score (>99.6%) to the global MPV genome database in 2022. Genetic variations in the primer-38 probe regions across MPV genomes could indicate the temporal and spatial emergence pattern of 39 monkeypox disease. Our results show that the current MPV real-time generic assay may not be 40 optimal to accurately detect MPV, and the mismatch-corrected assay with full complementarity 41 between primers and current MPV genomes could provide a more sensitive and accurate 42 detection of MPV. 43 44 45

46

47 Introduction

48 Our ability to detect emerging and re-emerging infectious disease agents has never been so 49 important as it is today. While the SARS-CoV-2 is gradually becoming an endemic virus, the 50 world is now seeing the re-emergence of the monkeypox virus (MPV). As of September 26, 51 2022, there were over 25,000 reported cases in the United States and over 66,000 cases in 106 countries¹. The World Health Organization (WHO) has declared a public health emergency of 52 53 international concern on July 23, 2022 to respond the rapid spread of MPV worldwide. 54 55 Monkeypox virus, a species of the Orthopoxvirus (OPV) genus, is a zoonotic double-stranded DNA virus with a ~197 kbp genome 2,3 . In 1970, monkeypox was first identified in humans in 56 the Democratic Republic of the Congo and in other African nations⁴. Sporadic monkeypox cases 57 58 were reported outside of Africa (U.S. and Europe), however, the infections were either related to international travel or exposure to animals imported from Africa ^{5,6}. The first MPV case 59 60 associated with the present outbreak was reported on May 6 in the United Kingdom, followed by cases in Spain, Portugal, and Canada ^{5,7}. On May 18, cases were reported in Belgium and Italy; 61 on May 20, cases were reported in Australia, France, Germany, and the Netherlands; and on May 62 21, cases were reported in Switzerland and Israel⁷. Such a wide outbreak within two weeks in 63 64 multiple counties across continents suggests that early non-reported transmission occurred before May 2022⁸. 65

66

The polymerase-chain reaction (PCR) has been used in the detection and diagnosis of viral
infections such as SARS-CoV-2. On June 6, 2022 the Centers for Disease Control and

69 Prevention (CDC) released a real-time PCR test using generic primers and probe for the

70	detection of MPV ⁹ based on previous work conducted in 2010 describing the detection of a
71	West African MPV strain and a Congo Basin MPV strain ¹⁰ . This MPV generic assay has been
72	used to identify human MPV infections and MPV present in wastewater samples ^{11,12} . Several
73	other real-time PCR assays have also been reported for MPV or OPV detection in clinical
74	samples ^{10,13–17} . However, the specificity and suitability of these generic primers and probes need
75	to be carefully addressed because most of the primers and probes (generic or lineage-specific)
76	were based on sequenced genomes obtained from MPV strains circulating more than a decade
77	ago (2002 to 2009). Given the rapid evolution of viral species, including DNA viruses ^{18,19} it is
78	likely that mutations have emerged in presently circulating MPV strains including the regions
79	targeted by those oligos used for MPV detection. The present report analyzes the oligo sequences
80	used in conjunction with the current real-time MPV assays by aligning primer sequences against
81	683 reported MPV complete genomes from GISAID as of August 5, 2022. This analysis
82	identified wide variations in the primer and probe sequences compared to the genome of
83	currently circulating MPV stains. Our results indicate that the current MPV real-time generic
84	assay may not be optimal to accurately detect MPV.
85	

86

87 Materials and Methods

Data source. The MPV genomes were downloaded from GISAID (https://gisaid.org/). As of

89 September 22 (10:50 am), 2022, 1,779 complete MPV genomes were available, including 1,730

- 90 genomes (samples) collected and sequenced in 2022. The remaining 49 samples include 7
- samples from 1962 to 2005, 11 samples collected in 2006, 12 samples in 2007, 7 samples in
- 92 2017, 8 samples in 2018, 2 samples in 2019, and 2 samples in 2021. In the United States, there

93	are 333 complete MPV genomes sampled from May 2022 to August 2022. Metadata includes
94	accession ID, sample collection date, sequence data submission date, and sampling location
95	(continent/country) associated with the sequences. The monkeypox virus reference genome
96	Zaire-96-I-16 was downloaded from NCBI (NC_003310.1). MPV real-time assays (primers and
97	probes) were from published studies including MPV Generic assay ⁹ , MPV_O2L ¹³ , MPV_F3L
98	¹⁴ , MPV_C3L ¹⁰ , MPV_G2R_WA ¹⁰ , OPV_B2R ¹⁵ , OPV_I7L ¹⁶ , and OPV_F8L ¹⁷ .
99	

100 Sequence alignment. Genome sequences were downloaded as *fasta* files and imported into R 101 (version 4.1.3) as the MPV genome database for analysis. We aligned each of the oligo 102 (including forward primer, reverse primer, and probe) sequences and their reverse complements 103 to the database and computed the percentage of genomes where the oligo sequences were a 100% 104 match. The MPV generic assay and the MPV_G2R_WA assay target two regions of the genome 105 (in inverted terminal repeats region), the other assays have one target. If the oligo is found in 106 more than one target but with different number of matches, the larger value is used as the 107 percentage of 100% match. For example, the forward primer used in the G2R_WA assay is 108 found in sense and antisense strands, but the number of 100% genome matches is 1,779 and 109 1,778, respectively, therefore, 1,779 was used to calculate the percentage of matching genomes. 110 For non-matches, sequences were extracted and aligned using SnapGene software 111 (https://www.snapgene.com/) to identify the specific nucleotides that differ between the oligos 112 and the genomic data. The major types of sequence variation(s) are listed in Figures 1 and 3A. In 113 total, the original sequence and identified sequence variations accounted for $99.2\% \sim 100\%$ of 114 the total genomes for the MPV real-time assays. These analyses were performed with customized 115 R script.

116

117	Real-time PCR. Quantitative PCR was performed with PCR primers and TaqMan probe. Briefly,
118	the real-time PCR Multiplex Supermix (Bio-Rad, Cat #: 12010220) was mixed with the primers,
119	probe, and nuclease-free H_2O (VWR, Cat #: 10220-402) and then added to respective wells of a
120	96-well PCR plate (Bio-Rad, Cat #: HSL9605). For MPV_FR-generic assay, forward primer
121	MPV-F-generic (5'-GGA AAA TGT AAA GAC AAC GAA TAC AG-3') and reverse primer
122	MPV-R-generic (5'-GCT ATC ACA TAA TCT GGA AGC GTA-3') were used; for MPV_FR-
123	m assay, mismatch-corrected primers, i.e., MPV-F-m (5'-GGA AAG TGT AAA GAC AAC
124	GAA TAC AG-3') and MPV-R-m (5'-GCT ATC ACA TAA TCT GAA AGC GTA-3'), were
125	used (Figure 1A). Probe MPV-P-generic (/56-FAM/AA GCC GTA A/ZEN/T CTA TGT TGT
126	CTA TCG TGT CC/3IABkFQ/) was used for both assays. All primers and probe were
127	synthesized from Integrated DNA Technologies (IDT) and final reaction concentrations were
128	500 nM and 250 nM, respectively. A 211-bp MPV DNA covering the primer and probe region
129	was synthesized at IDT and used as the PCR template. This synthetic DNA fragment is found in
130	96.71% (1,673 out of 1,730) of MPV genomes reported in 2022. The standard curves for the
131	MPV generic assay (with mismatches) and for the mismatch-corrected assay (with full
132	complementarity) were generated by serial ten-fold dilutions of the synthesized MPV gene
133	fragment from $2.16*10^{\circ}$ ~ $2.16*10^{7}$ copies/µL. Each concentration has three replicates, and the
134	mean value is used to build the standard curve. For a fine determination of the limit of detection
135	(LOD) for both assays, we used two-fold serial dilutions starting from 21.6 copies/ μ L and ran 16
136	replicates at each concentration tested. Another 16 replicates were performed to confirm results
137	for the mismatch-corrected assay at 1.3 copies/ μ L. Cycle threshold (C _t) values above 40 were
138	considered negative. The LOD is defined as the lowest concentration of targets at which more

139	than 95% of replicates are positive. The real-time PCR reactions were carried out using a Bio-
140	Rad CFX Opus 96 Detection System at the following conditions: polymerase activation (95 $^{\circ}$ C
141	for 3 min), PCR (48 cycles, denature at 95 °C for 3 s, and anneal/extend at 60 °C for 30 s).
142	
143	Mutation-based epidemiological analysis. For each MPV assay tested, we identified the major
144	variation type(s) in the genome database and then assigned an identity as 'match' or 'variation'
145	to each genome. Two variation types were found for the MPV_G2R_WA assay and were labeled
146	as 'Variation_1' and 'Variation_2', respectively. Merging with the metadata associated with the
147	genome, we summarized the number of genomes for 'match' and 'variation' groups based on the
148	sampling collection time (year), and sampling location (continent). We also sub-grouped the
149	database by only selecting the year '2022' to compute 'variation' percentages present in the
150	current MPV outbreak.
151	
152	Results
153	Generic MPV forward and reverse primers do not match the majority of reported genomes
154	To investigate whether forward and reverse primers and probe in the MPV generic assay match
155	to the genomes present in the current MPV outbreak, we aligned the three oligo sequences and
156	their reverse complements against the reported 1,730 complete genomes available in 2022. The
157	MPV generic forward sequence (MPV-F) had 100% identity to 4 genomes (0.23%). A single-

nucleotide mutation A194165G (synonymous mutation, MPV-F-m in Figure 1A) was found in

- 159 99.08% of the published MPV genomes in 2022 (Figure 1B), mostly from May to August 2022.
- 160 Similar observations were also found in the generic reverse primer (MPV-R), which only
- 161 matches to 1.73% of the genomes. A nonsynonymous substitution, G194233A in the reverse

primer region, was observed in 97.46% of the genomes. In contrast, the probe sequence (MPV-P)
is conserved and matches 99.31% of the genomes in the database.

164

We further compared the MPV generic primers and probe with sequenced samples from the U.S. Of the total of 330 genomes reported from May to August 2022, the A194165G mutation in the forward primer region was observed in all U.S. genomes, and the G194233A mutation observed in the reverse primer was found in 97.58% of the U.S. genomes (Figure 1C) consistent with the results in Figure 1B. These results show that the CDC recommended forward and reverse primers used for MPV generic testing are not 100% identical to the major genome sequences in recent samples with MPV.

172

173 Mismatch-corrected primers have improved quantification and lower limits of detection. 174 Some studies have reported positive detection of MPV in clinical and wastewater samples using the generic real-time assay ^{11,12}, suggesting that these primers can amplify the targeted region 175 176 even with a substitution in each of the primers. We therefore evaluated the real-time PCR 177 performance for the generic primers (FR_generic) and new primers with mismatches corrected 178 (FR_match) using a synthesized 211-bp MPV gene fragment (found in 96.71% of genomes in 179 2022) covering the primer and probe region. Standard curves from serial 7-log dilutions show that both assays have similar amplification efficiencies with $R^2 > 0.99$ (Figure 2A-B). Under the 180 181 same concentrations of MPV gene template ranging from 2.16 ~ 2.16e7 copies/µL, MPV 182 FR_generic has a consistently higher Ct values (3.46±0.39) than FR_match, suggesting that the 183 two mismatches in FR generic primers cause about 11-fold underestimation of the initial 184 template concentration (Figure 2C). We next evaluated the limit of detection (LOD) by

185	conducting 2X dilutions of template DNA, and each has ~16 replicates. The 95% LOD for
186	FR_generic assay is 10.8 copies per reaction while the FR_match is 2.7 copies per reaction
187	(Table 1). Together, these results showed that the current MPV generic assay could still detect
188	MPV, but the template concentration quantified from this assay is underestimated by about an
189	order of magnitude. In addition, the mismatch-corrected primers have a lower 95% limit of
190	detection, which is important for samples with low MPV concentrations.
191	
192	Evaluation of the specificity of other primers and probes for monkeypox virus and

193 orthopoxvirus (OPV) detection.

Next, we evaluated seven other developed real-time PCR assays, targeting O2L, F3L, C3L, and 194 195 G2R genes for MPV, B2R, I7L and F8L genes for OPV detection. The selected targets are generally conserved regions within viral genomes to maximize viral detection ^{13,15}. We aligned 196 197 primer and probe sequences and their reverse complements in the seven assays against the total 198 1,779 MPV genomes and computed the percentage of genomes with a 100% match. As shown in 199 Table 1, the four reported assays designed for MPV detection have varied results. The primers in 200 MPV_O2L have a ~99% match with the database, but the probe only matches 1.8% of genomes. 201 This ratio goes down to 0.23% when aligned to the genomes in 2022. Primers and probe 202 sequences used in the MPV F3L assay matches >99.7% of the genomes, suggesting its 203 suitability for detection of the MPV-2022 outbreak. The MPV C3L assay designed for the 204 detection of the MPV Congo Basin strain poorly matches to the current MPV genomes (0.23%). 205 Primers used in the MPV_G2R_WA assay designed to detect the West African strain showed a 206 100% match to the database and 99.65% match for the probe, thereby validating previous phylogenetic analysis results that the current MPV lineage belonging to the West Africa clade ²⁰. 207

2	n	Q
2	υ	0

209	We further evaluated three real-time assays (OPV_B2R, OPV_I7L, and OPV_F8L) for the
210	detection of viruses belonging to the Orthopoxvirus genus, which includes monkeypox virus,
211	camelpox virus, cowpox virus, and vaccinia virus ²¹ . OPV_B2R primers highly match the
212	database genomes, but its probe sequence has no match (Table 2). OPV_I7L has good matches
213	for the forward primer and probe, but its reverse primer only matches 1.56% of the genomes.
214	OPV_F8L oligos for the non-variola OPV generic test recommended by CDC has a high match
215	percentage (>99%) with the genomes (Table 2). Thus, the MPV_F3L, MPV_G2R_WA, and
216	OPV_F8L assays matches to >99% of the sequenced MPV genomes.
217	
218	Genetic variations across real-time PCR assays for MPV or OPV detection and
219	epidemiological analysis.
220	Probes in MPV_O2L and OPV_B2R and reverse primer in OPV_I7L match 0 ~ 1.56% of the
221	genomes, suggesting potential variations in the current MPV genomes. We next analyzed MPV
222	genomic sequences to identify the main variations. About 98% of the MPV genomes have a G-
223	>T mutation in the probe used in MPV_O2L assay, and this mutation is present in 99.48% of the
224	MPV-2022 outbreak genomes (Figure 3A). Further analysis based on the sample collection date
225	identified this G->T mutation in two samples in 1962 and 1970, was not detected in samples
226	from 1978 to 2007, and re-emerged from 2017 onward and became dominant in current outbreak
227	(Figure 3B). For the OPV_I7L assay, a C->T mutation was observed at the 3' end of the reverse
228	primer in 95.11% of all genomes and in 97.75% of genomes sequenced in 2022. It is interesting
229	that this mutation is mostly observed in samples from Europe, South, and North America
230	whereas the original sequence was more common in samples from Africa and Asia (Figure 3C).

A G->C substitution in the probe sequence of OPV_B2R was observed in nearly all genomes
sequenced in the MPV-2022 outbreak (Figure 3A).

233

The MPV_G2R_WA assay probe has a 98.09% match to the database sequences (Figure 3A).

Two variation types were found for the rest of the 1.91% genomes. A 7-nucleotide variation

(variation_1) was found in 28 genomes from 1978 to 2007 (Figure 3A and 3D). Variation_1

reappears in 2022 in one male patient's sample (age 50) from Luxembourg, and four children

samples (age 3 to 10) from Tshopo and Kwilu provinces in the Democratic Republic of the

239 Congo. Although 99.54% of the 2022 MPV genomes are conserved in this probe region, one new

240 C->T synonymous variation (variation_2) (Figure 3A) was identified from a sample obtained on

241 May 18, 2022 from Canada. Those results suggest that the genetic variations in MPV conserved

242 genomic regions covering the real-time PCR primer and probe sequences might be used to

indicate the temporal and spatial emergence pattern of monkeypox disease.

244

245 Discussion

Accurate diagnostics are fundamental for successful epidemic control ²². PCR-based molecular 246 247 methods are widely used for pathogen detection in clinical and environmental samples. As a 248 rapid and reliable tool, TaqMan real-time PCR offers high sensitivity and specificity that targets 249 a respective pathogen's genome by using a designed probe, and forward and reverse primers. 250 Therefore, an exact match between the three oligos and the target genome are required for 251 sensitive and accurate diagnostics. Here, we analyzed the sequence of primers and probe used in 252 the CDC recommended MPV generic real-time PCR assay as well as seven other MPV and OPV 253 diagnostic assays by aligning respective primer/probe sequences against published MPV full

genomes. Our results showed two mismatches in more than 99% of genomes for the MPV
generic forward and reverse primers (Figure 1). One mutation G194233A is close to the 3' end
of the reverse primer, suggesting it may significantly impact the binding efficiency during
amplification.

258

259

reduce thermal stability of the primer-template DNA duplex and impact PCR performance ^{23,24}.
Mismatches have often been reported to undermine real-time PCR based diagnostics.
Stadhouders *et al.* examined the impact of primer-template mismatches and found that one G→A mismatch at the 3'end of primer could lead to an increase of >8 Ct values depending on the

Theoretically, every mismatch, irrespective of its position within the primer sequence could

264 position ²⁴. Klungthong *et al.* found a single mismatch at the 3^{rd} base of the probe significantly

reduced sensitivity for detection of influenza A/H1N1/2009²⁵. In another study, Persson et al

266 reported that that a single $G \rightarrow T$ mismatch at 3' -end of the reverse primer for detection of

267 hepatitis A virus by RT-PCR assay causes underestimation of the template concentration by a

268 factor of 1.7–1.8 and an \sim 2-fold increase in 95% LOD ²⁶.

269

The two identified mismatches, despite neither of them being at the 1st position of 3' end, may have combined effects on PCR performance. We thus synthesized primers with an identical match to the MPV genome and compared results generated by the assay with mismatches. Our results showed that the two primer-template mismatches resulted in a ~11-fold underestimation of initial template DNA in the reaction and 4-fold increase in the 95% LOD in our real-time PCR settings. Those results indicated that the mismatch-corrected assay with full complementarity between primers and current MPV genomes could provide a more sensitive detection of MPV,

277 which is important for samples with low viral concentrations such as wastewater 2^{7-30} .

278 Furthermore, the fully matched primers showed an improved quantification of the initial DNA

279 concentration needed for the quantitative analysis associated with tracking disease progression or

assessing estimates of prevalence.

281

282 Of the seven other assays evaluated for MPV or OPV detection, MPV_F3L, MPV_G2R_WA, 283 and OPV F8L had the highest matches (>99%) to the 2022 global genome database. However, 284 specificity, another important parameter for real-time PCR-based diagnostics, needs further 285 investigation for these three assays. For example, we found that primers and probe in the 286 MPV_F3L assay had high a homology to OM460002.1 cowpox virus isolate No-H2 genome 287 (two mismatches in the probe and reverse primer), suggesting it could also amplify cowpox virus. 288 On the other hand, the choice for the three assays may also depend on the sample types. For 289 example, the three assays may work well for clinical samples and provide reliable diagnostics for 290 human MPV. However, extra attention is needed to interpret positive results for wastewater 291 samples, which may contain waste of human, cat, dog, mice, rabbits, and cow origins ³¹.

292

It is necessary to mention that sequence matching is just one of the parameters determining the detection sensitivity and specificity. Other parameters such as primer dimer formation, GC content, the quality of the template DNA, the PCR master mix, and inhibitors present in the sample may also impact the diagnostic efficiency and mismatch-induced effects ^{24,32,33}. An ideal diagnostic assay needs to consider and assess those factors in a comprehensive way. This study used a synthetic MPV gene fragment to test the mismatch effects, but it is recommended to

verify the results using a full-length viral genome, which may introduce more complexity and
even increase the underestimation ²⁶.

301

- 302 In summary, our analysis showed that primers and probe in the recommended MPV generic real-
- 303 time assay harbor wide deviations from the sequenced MPV genomes, especially the genomes
- 304 released in current monkeypox outbreak. The mismatch-corrected assay, harboring full
- 305 complementarity to >97% MPV genomes, shows a higher sensitivity and improved
- 306 quantification and may be an alternative approach for the MPV detection. Improved diagnostic
- 307 capabilities are critical as public health practitioners and clinicians respond to the growing MPV
- 308 outbreak.

309

- **310 Declaration of Competing Interest**
- 311 The authors declare no competing interest.
- 312
- 313 Code Availability

All data and code produced in the present study are available upon reasonable request to theauthors.

316

317 Acknowledgement

318 We are grateful to Dr. Alanna Morrison and the colleagues in the TEPHI for helpful discussion.

319 This work is supported by Faculty Startup funding from the Center of Infectious Diseases at

320 UTHealth, the UT system Rising STARs award, and the Texas Epidemic Public Health Institute

321 (TEPHI).

322

323 Ethical Approval Statement


- 324 This article does not contain any studies involving animals or humans performed by any authors.
- 325

326 **Reference**

- CDC. 2022 Monkeypox Outbreak Global Map. Centers for Disease Control and Prevention.
 Published June 24, 2022. Accessed August 9, 2022.
- 329 https://www.cdc.gov/poxvirus/monkeypox/lab-personnel/index.html
- Petersen E, Kantele A, Koopmans M, et al. Human Monkeypox: Epidemiologic and Clinical
 Characteristics, Diagnosis, and Prevention. *Infectious Disease Clinics*. 2019;33(4):1027 1043. doi:10.1016/j.idc.2019.03.001
- Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical effect of the
 emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and
 hospital-based cohort study. *The Lancet Infectious Diseases*. 2021;21(9):1246-1256.
 doi:10.1016/S1473-3099(21)00170-5
- Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bull World Health Organ*. 1980;58(2):165-182.
- Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox Virus Infection in Humans across 16
 Countries April–June 2022. *New England Journal of Medicine*. 2022;0(0):null.
 doi:10.1056/NEJMoa2207323
- Titanji BK, Tegomoh B, Nematollahi S, Konomos M, Kulkarni PA. Monkeypox: A
 Contemporary Review for Healthcare Professionals. *Open Forum Infectious Diseases*.
 2022;9(7):ofac310. doi:10.1093/ofid/ofac310
- Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the
 pathobiology of the monkeypox virus. *Journal of Autoimmunity*. 2022;131:102855.
 doi:10.1016/j.jaut.2022.102855
- Vivancos R, Anderson C, Blomquist P, et al. Community transmission of monkeypox in the
 United Kingdom, April to May 2022. *Euro Surveill*. 2022;27(22):2200422.
 doi:10.2807/1560-7917.ES.2022.27.22.2200422
- CDC. Test Procedure: Monkeypox virus Generic Real-Time PCR Test. Centers for Disease
 Control and Prevention. Published June 6, 2022. Accessed August 9, 2022.
 https://www.cdc.gov/poxvirus/monkeypox/pdf/PCR-Diagnostic-Protocol-508.pdf
 - 15

- 10. Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. Real-time PCR assays for the specific
 detection of monkeypox virus West African and Congo Basin strain DNA. *J Virol Methods*.
 2010;169(1):223-227. doi:10.1016/j.jviromet.2010.07.012
- 11. Peiró-Mestres A, Fuertes I, Camprubí-Ferrer D, et al. Frequent detection of monkeypox virus
 DNA in saliva, semen, and other clinical samples from 12 patients, Barcelona, Spain, May to
 June 2022. *Eurosurveillance*. 2022;27(28):2200503. doi:10.2807/1560-
- **360** 7917.ES.2022.27.28.2200503
- Wolfe MK, Duong D, Hughes B, Chan-Herur V, White BJ, Boehm AB. Detection of
 monkeypox viral DNA in a routine wastewater monitoring program. Published online July
 26, 2022:2022.07.25.22278043. doi:10.1101/2022.07.25.22278043
- 364 13. Wawina-Bokalanga T, Sklenovska N, Vanmechelen B, et al. An accurate and rapid Real365 time PCR approach for human Monkeypox virus diagnosis. Published online June 23,
 366 2022:2022.06.23.22276033. doi:10.1101/2022.06.23.22276033
- Maksyutov RA, Gavrilova EV, Shchelkunov SN. Species-specific differentiation of variola,
 monkeypox, and varicella-zoster viruses by multiplex real-time PCR assay. *J Virol Methods*.
 2016;236:215-220. doi:10.1016/j.jviromet.2016.07.024
- Stellberger T, Stockmar I, Haase M, et al. Multiplex Real-Time PCR Assay for the Detection
 and Differentiation of Poxviruses and Poxvirus Vectors. *Applied Biosafety*.
 2015;20(4):192-200. doi:10.1177/153567601502000405
- 373 16. Schroeder K, Nitsche A. Multicolour, multiplex real-time PCR assay for the detection of
 374 human-pathogenic poxviruses. *Mol Cell Probes*. 2010;24(2):110-113.
 375 doi:10.1016/j.mcp.2009.10.008
- 17. CDC. Test Procedure: Non-variola Orthopoxvirus Generic Real-Time PCR Test. Published
 June 6, 2022. https://www.cdc.gov/poxvirus/monkeypox/pdf/non-variola-orthopoxvirus generic-real-time-pcr-test.pdf
- 18. Nasir A, Caetano-Anollés G. A phylogenomic data-driven exploration of viral origins and
 evolution. *Science Advances*. 2015;1(8):e1500527. doi:10.1126/sciadv.1500527
- 19. Villarreal LP. Evolution of Viruses. *Encyclopedia of Virology*. Published online 2008:174184. doi:10.1016/B978-012374410-4.00706-8
- Wang L, Shang J, Weng S, et al. Genomic annotation and molecular evolution of
 monkeypox virus outbreak in 2022. *Journal of Medical Virology*. 2022;1(7).
 doi:10.1002/jmv.28036
- 21. Petersen BW, Karem KL, Damon IK. Orthopoxviruses: Variola, Vaccinia, Cowpox, and
 Monkeypox. In: Kaslow RA, Stanberry LR, Le Duc JW, eds. *Viral Infections of Humans: Epidemiology and Control*. Springer US; 2014:501-517. doi:10.1007/978-1-4899-7448-8_21


- Kelly-Cirino CD, Nkengasong J, Kettler H, et al. Importance of diagnostics in epidemic and
 pandemic preparedness. *BMJ Glob Health*. 2019;4(Suppl 2):e001179. doi:10.1136/bmjgh 2018-001179
- 392 23. So KYK, Fong JJ, Lam IPY, Dudgeon D. Pitfalls during in silico prediction of primer
 393 specificity for eDNA surveillance. *Ecosphere*. 2020;11(7):e03193. doi:10.1002/ecs2.3193
- Stadhouders R, Pas SD, Anber J, Voermans J, Mes THM, Schutten M. The Effect of PrimerTemplate Mismatches on the Detection and Quantification of Nucleic Acids Using the 5'
 Nuclease Assay. *The Journal of Molecular Diagnostics*. 2010;12(1):109-117.
 doi:10.2353/jmoldx.2010.090035
- 398 25. Klungthong C, Chinnawirotpisan P, Hussem K, et al. The impact of primer and probe399 template mismatches on the sensitivity of pandemic influenza A/H1N1/2009 virus detection
 400 by real-time RT-PCR. *J Clin Virol*. 2010;48(2):91-95. doi:10.1016/j.jcv.2010.03.012
- 26. Persson S, Karlsson M, Borsch-Reniers H, Ellström P, Eriksson R, Simonsson M. Missing
 the Match Might Not Cost You the Game: Primer-Template Mismatches Studied in Different
 Hepatitis A Virus Variants. *Food Environ Virol*. 2019;11(3):297-308. doi:10.1007/s12560019-09387-z
- 405 27. Wu F, Zhang J, Xiao A, et al. SARS-CoV-2 Titers in Wastewater Are Higher than Expected
 406 from Clinically Confirmed Cases. *mSystems*. 2020;5(4):e00614-20.
 407 doi:10.1128/mSystems.00614-20
- 408 28. Wu F, Lee WL, Chen H, et al. Making Waves: Wastewater Surveillance of SARS-CoV-2 in
 409 an Endemic Future. *Water Research*. Published online May 3, 2022:118535.
 410 doi:10.1016/j.watres.2022.118535
- 411 29. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
 412 with COVID-2019. *Nature*. 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x
- 30. Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during
 SARS-CoV-2 human challenge in young adults. *Nat Med.* Published online March 31,
 2022:1-11. doi:10.1038/s41591-022-01780-9
- 416 31. Smyth DS, Trujillo M, Gregory DA, et al. Tracking cryptic SARS-CoV-2 lineages detected
 417 in NYC wastewater. *Nat Commun.* 2022;13(1):635. doi:10.1038/s41467-022-28246-3
- 418 32. Kralik P, Ricchi M. A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions,
 419 Parameters, and Everything. *Frontiers in Microbiology*. 2017;8. Accessed August 10, 2022.
 420 https://www.frontiersin.org/articles/10.3389/fmicb.2017.00108
- 33. Ruijter JM, Ramakers C, Hoogaars WMH, et al. Amplification efficiency: linking baseline
 and bias in the analysis of quantitative PCR data. *Nucleic Acids Res.* 2009;37(6):e45.
 doi:10.1093/nar/gkp045
- 424





441 Figure 1. MPV generic forward and reverse primers do not match to the majority of

- 442 reported genomes. (A) Alignment of MPV generic forward primer, reverse primer, and probe
- sequences (recommended in the CDC test procedure for MPV ⁹) to the MPV reference genome
- 444 (MPV-Zaire-96-I-16). The corresponding oligo sequences with mismatches found in the genome
- 445 database for forward (MPV-F-m) and reverse primers (MPV-R-m) were also added on top of the
- 446 reference genome. Red nucleotides indicate genetic variations identified in the MPV genome
- 447 database and the nonsynonymous mutation is marketed by a red box. (B-C) The abundance of
- 448 MPV-F (generic) and MPV-F-m, MPV-R (generic) and MPV-R-m in the currently available
- 449 1,730 MPV genomes worldwide published in 2022 (B), and in the 330 U.S. genomes (C).





corrected assay. (A-B) Standard curves for MPV FR_generic (A) and FR_match (B) assays.

Data shown represent the mean of three replicates with standard deviations. Trendlines with

trendline equations and coefficient of determination were added. (C) Mismatch-corrected assay

- (FR_match) has lower Ct values under the same concentrations of initial template DNA.






Figure 3. Genetic variations across real-time PCR assays for MPV or OPV detection and epidemiological analysis. (A) Genetic variations in the MPV genome database compared to primer and probe sequences used in detection assays. (B) Temporal analysis for the genetic variation in MPV_O2L probe sequence. This variation is found in 99.48% of the genomes in 2022. (C) Proportion of genomes for the reverse primer used in the OPV_I7L assay with or without variation by continent. (D) Incidence of MPV_G2R_WA probe sequence and its two variation types across the genomic database by year.

- 469
- 470
- 471
- 472

Table 1. Limits of detection for MPV generic assay (FR_generic) and mismatch-corrected assay

474 (FR_match).

	DNA template	Synthetic MPV gene fragment concentrations (copies / mL)						
	volume (µl)	21,622	10,811	5,405	2,703	1,351	676	0
FR_generic	2	100% (16/16)	100% (16/16)	100% (16/16)	75% (12/16)	50% (8/16)	Not tested	12.5% (2/16
FR_match	2	100% (14/14)	100% (16/16)	100% (16/16)	100% (16/16)	100% (32/32)	81% (13/16)	0% (0/16)

478

475 476 477

Table 2. Evaluation of the sequence specificity of primers and probes for monkeypox virus (MPV) or orthopoxvirus (OPV) detection.

481

Target	Oligo ¹	Oligo sequence (5'->3')	Percentage for 100% match (total MPV genomes, N=1,779) ²	Percentage for 100% match (genomes in 2022, N=1,730) ²
MPV_02L	Forward (+) Reverse (+) Probe (+)		99.78% 98.99% 1.80%	99.77% 98.96% 0.23%
MPV_F3L	Forward (+) Reverse (+) Probe (+)	CATCTATTATAGCATCAGCATCAGA GATACTCCTCCTCGTTGGTCTAC TGTAGGCCGTGTATCAGCATCCATT	99.72% 99.83% 99.78%	99.71% 99.83% 99.77%
MPV_C3L	Forward (-) Reverse (-) Probe (-)		1.80% 1.80% 1.80%	0.23% 0.23% 0.23%
MPV_ G2R_WA	Forward (±) Reverse (±) Probe (±)	CACACCGTCTCTTCCACAGA GATACAGGTTAATTTCCACATCG AACCCGTCGTAACCAGCAATACATTT	100.0% 100.0% 98.09%	100.00% 100.00% 99.65%
OPV_B2R	Forward (+) Reverse (+) Probe (-)		99.83% 99.83% 0.00%	99.83% 99.83% 0.00%
OPV_I7L	Forward (+) Reverse (+) Probe (+)	TAATACTTCGATTGCTCATCCAGG ACTTCTCACAAATGGATTTGAAAATC TCCTTTACGTGATAAATCAT	99.27% 4.22% 99.55%	99.25% 1.56% 99.54%
OPV_F8L	Probe (-)	GAGTATAGAGCACTATTTCTAAATCCCA	99.16%	99.36% 99.19% 99.13%

482 $\begin{bmatrix} -1 \\ + \end{bmatrix}$: indicates sense strand; (-) indicates anti-sense strand; (\pm) indicates that oligo has two binding sites, one each on sense

483 and antisense strand.

484 ²: This is the percentage of complete genomes that the primer/probe sequence can 100% match with at least one target site. As

485 of September 22 (10:50am), there are 1,779 complete genomes published in GISAID, of which 1,730 are published in 2022.